Human monoclonal single‐chain antibodies specific to dengue virus envelope protein. (1st March 2014)

• Record Type: Journal Article
• Authors: Saokaew, N.; Poungpair, O.; Panya, A.; Tarasuk, M.; Sawasdee, N.; Limjindaporn, T.; Chaicumpa, W.; Yenchitsomanus, P.
• Is Part Of: Letters in applied microbiology. Volume 58:Number 3(2014:Mar.)
• Page Start: 270
• Page End: 277
• Publication Date: 2014-03-01
• Subjects: dengue virus -- envelope protein -- human single‐chain variable fragments -- monoclonal antibody -- phage display -- virus entry; Microbiology -- Periodicals; 660.62
• DOI: 10.1111/lam.12186
• Languages: English
• ISSNs: 0266-8254

Abstract

Abstract: Dengue virus (DENV) infection is an arthropod‐borne disease with increasing prevalence worldwide. Attempts have been made to develop therapeutic molecules for treatment for DENV infection. However, most of potentially therapeutic DENV monoclonal antibody was originated from mouse, which could cause undesirable effects in human recipients. Thus, fully human antibody is preferable for therapeutic development. Human single‐chain variable fragments (HuScFv) with inhibitory effect to DENV infection were generated in this study. HuScFv molecules were screened and selected from the human antibody phage display library by using purified recombinant DENV full‐length envelope (FL‐E) and its domain III (EDIII) proteins as target antigens for biopanning. HuScFv molecules were then tested for their bindings to DENV particles by indirect ELISA and immunofluorescent microscopy. EDIII‐specific HuScFv exhibited neutralizing effect to DENV infection in Vero cells in a dose‐dependent manner as determined by plaque formation and cell ELISA. Epitope mapping and molecular docking results concordantly revealed interaction of HuScFv to functional loop structure in EDIII of the DENV E protein. The neutralizing HuScFv molecule warrants further development as a therapeutic biomolecule for DENV infection. Significance and Impact of the Study: No approved vaccine and specific drug for dengue virus (DENV) infection are available; thus, their developments are urgently required. The human single‐chain variable antibody fragments (HuScFv) specific to DENV envelope (E) protein are potential to be developed as therapeutic biomolecules. HuScFv that bound specifically to recombinant full‐length DENV E (FL‐E) and its domain III (EDIII) were generated and testified for its inhibitory effect in DENV infection. EDIII‐specific HuScFv inhibited DENV infection in a dose‐dependent manner and has potential to be further developed as a therapeutic biomolecule for DENV infection.